Elevance Health stock gains after raised outlook and analyst target
Published on 11/05/2026 at 16:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOutlook and valuation remain in focus
- Elevance Health raised its adjusted 2026 earnings guidance to at least 29.00 US dollars per share.
- Wells Fargo lifted its price target to 492 US dollars while retaining an Overweight rating.
- Medicaid, exchange trends, membership and health-plan margins remain key tests for the investment case.
Elevance Health's latest earnings update and a higher analyst target have strengthened the near-term reference points for investors, while membership and margin trends remain important counterweights.
The company reported its third-quarter results on October 21, 2026, and raised adjusted diluted earnings guidance for fiscal 2026 to at least 29.00 US dollars per share. Operating revenue reached 50.4 billion US dollars, up 0.7 percent from the prior-year quarter, while adjusted diluted earnings per share came to 6.99 US dollars. Elevance Health also raised full-year operating cash flow guidance to at least 6.5 billion US dollars, according to the Elevance Health release.
What has changed since the last report
The previous report cited a 377.45-euro indication on November 4. The [real-time quote of Elevance Health stock](https://www.ad-hoc-news.de/boerse/aktie/snapshot/US0367521038-elevance-health-aktie) showed Elevance Health stock traded at 395.40 euros on Lang & Schwarz at 16:32 CET on Thursday, November 5, 2026. The move since that report is separate from a daily Xetra comparison.
Wells Fargo raised its target for Elevance Health from 473 to 492 US dollars on October 27 and retained an Overweight rating. The bank cited constructive trends in Medicaid and health insurance exchanges, while also pointing to Medicare Advantage. Its 2026 earnings estimate rose by 2.00 US dollars to 30.28 US dollars per share, according to Investing.com.
Margins and membership set the next test
The stronger earnings framework does not remove execution risk. Investors will continue to watch Medicaid and Affordable Care Act margins, Medicare Advantage membership and the development of health-plan costs. The company said its adjusted diluted earnings baseline for 2027 was at least 26.75 US dollars and reiterated a goal of at least 12 percent adjusted earnings-per-share growth in 2027.
Elevance Health at a glance
- Company: Elevance Health Inc.
- ISIN: US0367521038
- NYSE ticker: ELV
- Lang & Schwarz quote: 395.40 euros at 16:32 CET on November 5, 2026
- Previous report reference: 377.45 euros on November 4, 2026
US health insurers remain sensitive to policy expectations, medical-cost trends and government-sponsored plan economics. Current market reports provide the broader S&P 500 context.
